JACC. Heart failure最新文献

{"title":"Outcomes after DCD Cardiac Transplantation: An international, multicenter retrospective study.","authors":"John O Louca,Marco Öchsner,Sai Bhagra,Ashish Shah,Kelly Schlendorf,Brian Lima,Chen Chia Wang,Hasan Siddiqi,Ali Irshad,Jacob Schroder,Sarah Casalinova,Carmelo Milano,Kiran Khush,Anette Skoda,Helen Luikart,Euan Ashley,Nader Moazami,Les James,Owais Dar,Mailen Konicoff,Marian Urban,John Um,Anthony Castleberry,Jordan R H Hoffman,Sarah Y Park,Michael T Cain,Katharina Fetten,Dan Meyer,Addison Xu,Francisco Gonzalez-Vilchez,Beatriz Domínguez-Gil,Mario Royo-Villanova,Iris Garrido,Janne Brouckaert,Filip Rega,Vincent Tchana-Sato,Marius Berman,James Bae,Sanjay Sinha,Stephen Pettit,Simon Messer,Stephen Large,","doi":"10.1016/j.jchf.2025.04.003","DOIUrl":"https://doi.org/10.1016/j.jchf.2025.04.003","url":null,"abstract":"BACKGROUNDAs donation after circulatory determination of death (DCD) heart transplantation (HT) becomes more widely adopted, there is a need to establish the most clinically effective method of organ procurement.OBJECTIVEThis international, multicenter study compares outcomes of DCD-HT across Europe and the United States (US) between recipients whose donor hearts were retrieved using thoraco-abdominal normothermic regional perfusion (taNRP) to those whose hearts were recovered using direct procurement and perfusion (DPP).METHODSThis was a retrospective observational study across 20 heart transplant centers in Belgium, Spain, the United Kingdom (UK) and the US. This study included all patients undergoing DCD-HT at participating centers, from the start of each center's DCD program through 01/01/2023. DCD-HT with recovery using either taNRP or DPP were compared to one-another. Post-transplant outcomes included (i)survival at 1-year, (ii)incidence of severe primary graft dysfunction (PGD), (iii)episodes of treated, biopsy-proven acute-cellular rejection (ACR) in the first year following transplantation.RESULTS504 DCD-HT took place in the study period. Survival at one year was similar for taNRP and DPP recipients (91% vs 88%, p=0.1). taNRP recipients had a lower rate of severe PGD (7.6% vs 19.2%, p<0.001) and fewer episodes of biopsy-proven, ACR requiring treatment in the first-year post-transplantation (13% vs 25%,p<0.001).CONCLUSIONIn an international study of DCD-HT, recipients of hearts retrieved by taNRP technique had lower rates of severe PGD and fewer episodes of biopsy-proven ACR in the first year when compared with those retrieved utilizing DPP. These results should be further investigated with randomized control trials.","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"15 1","pages":""},"PeriodicalIF":13.0,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143889260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"DANGERous Extrapolations Within and Beyond STEMI Cardiogenic Shock.","authors":"Francesco Castagna,Akshay S Desai,Mandeep R Mehra","doi":"10.1016/j.jchf.2025.04.004","DOIUrl":"https://doi.org/10.1016/j.jchf.2025.04.004","url":null,"abstract":"","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"9 1","pages":""},"PeriodicalIF":13.0,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143889259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First-in-Human Implantable Inferior Vena Cava Sensor for Remote Care in Heart Failure: FUTURE-HF","authors":"Paul R. Kalra MA MB BChir MD, Irakli Gogorishvili MD, George Khabeishvili MD, Filip Málek MD PhD MBA, Ondřej Toman PhD MHA, Chris Critoph BM MD, Andrew S. Flett MBBS MD CCDS, Peter J. Cowburn MD, Mandeep R. Mehra MD MSc, William S. Sheridan PhD, John R. Britton PhD MBA, Teresa Buxo MSc, Robyn M. Kealy MSc, Annette Kent PhD, Barry R. Greene PhD, Kaushik Guha MD, Roy S. Gardner MBChB MD, Ian Loke MBChB MD, Ali Vazir PhD MBBS, Jasper J. Brugts MD PhD MSc, Alastair Gray MBChB MD, Jeffrey M. Testani MD MTR, Kevin Damman MD PhD","doi":"10.1016/j.jchf.2025.01.019","DOIUrl":"https://doi.org/10.1016/j.jchf.2025.01.019","url":null,"abstract":"Variations of inferior vena cava (IVC) area and collapsibility serve as early markers of congestion and predict risk for heart failure (HF) events.","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"5 1","pages":""},"PeriodicalIF":13.0,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143824979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An Innovative Program for Evidence Generation","authors":"Mona Fiuzat PharmD ,&nbsp;Kimberly Ferlin PhD ,&nbsp;Laura Gottschalk PhD ,&nbsp;Andrew Farb MD ,&nbsp;Isabella Cavagna BS ,&nbsp;JoAnn Lindenfeld MD ,&nbsp;Bram Zuckerman MD ,&nbsp;Douglas Kelly MD ,&nbsp;Heart Failure Collaboratory","doi":"10.1016/j.jchf.2025.01.011","DOIUrl":"10.1016/j.jchf.2025.01.011","url":null,"abstract":"","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"13 4","pages":"Pages 647-650"},"PeriodicalIF":10.3,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143633626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of Heart Failure With Improved Ejection Fraction","authors":"Nandan Kodur BS ,&nbsp;W.H. Wilson Tang MD","doi":"10.1016/j.jchf.2025.02.007","DOIUrl":"10.1016/j.jchf.2025.02.007","url":null,"abstract":"<div><div>Heart failure with improved ejection fraction (HFimpEF) is defined by improved left ventricular ejection fraction (LVEF) among patients who previously had reduced LVEF. HFimpEF is associated with improved prognosis, albeit with persistent risk of relapse and adverse events in some patients. Current guidelines thus recommend sustained and indefinite guideline-directed medical therapy (GDMT) for all patients with HFimpEF. Emerging clinical experience suggests that heart failure arising from acute etiologies that fully resolve along with complete LVEF recovery may have a favorable prognosis with lower risk of relapse. Indeed, cohort and case series studies have demonstrated the feasibility of safe de-escalation of GDMT in select patients with specific etiologies, with multiple small trials ongoing. Future studies should investigate whether advanced imaging or blood biomarkers could aid in risk stratifying patients with recovered LVEF, whether partial de-escalation of GDMT could be safe and feasible, and whether implantable cardioverter-defibrillator therapy can be safely discontinued.</div></div>","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"13 4","pages":"Pages 537-553"},"PeriodicalIF":10.3,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143790922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early Detection of Cardiorespiratory Diseases at Everton BEAT-Breathlessness Community Hub","authors":"Rajiv Sankaranarayanan MBBS, PhD ,&nbsp;Nick Hartshorne-Evans ,&nbsp;Lucy Mclean BSc, MPH ,&nbsp;Jonathan Jones BSc, MSc ,&nbsp;Michael Salla BSc, MSc, MPH ,&nbsp;Biswajit Chakrabarti MBBS, MD ,&nbsp;Justine Hadcroft MBBCh, MD ,&nbsp;Christopher Pritchard BSc(Hons), MBChB ,&nbsp;Andy Smith PhD, MA, BSc ,&nbsp;Carolyn S.P. Lam MBBS, PhD, MS","doi":"10.1016/j.jchf.2025.01.008","DOIUrl":"10.1016/j.jchf.2025.01.008","url":null,"abstract":"","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"13 4","pages":"Pages 663-665"},"PeriodicalIF":10.3,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143567150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ultrafiltration for Management of Decompensated Heart Failure","authors":"Sean P. Pinney MD ,&nbsp;Maria V. DeVita MD ,&nbsp;Bjorn Redfors MD, PhD ,&nbsp;Lak N. Kotinkaduwa PhD ,&nbsp;Megan Cotts BS ,&nbsp;Jennifer Cowger MD, MS ,&nbsp;Maria Rosa Costanzo MD","doi":"10.1016/j.jchf.2024.11.018","DOIUrl":"10.1016/j.jchf.2024.11.018","url":null,"abstract":"","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"13 4","pages":"Pages 657-659"},"PeriodicalIF":10.3,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143476492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Standardizing Histopathological Evaluation of Resected Myocardium in Obstructive Hypertrophic Cardiomyopathy","authors":"Ahmad Masri MD, MS","doi":"10.1016/j.jchf.2025.01.012","DOIUrl":"10.1016/j.jchf.2025.01.012","url":null,"abstract":"","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"13 4","pages":"Pages 641-643"},"PeriodicalIF":10.3,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143673258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Growth Hormone Replacement Therapy in Heart Failure With Reduced Ejection Fraction","authors":"Alberto Maria Marra MD, PhD ,&nbsp;Roberta D’Assante PhD ,&nbsp;Mariarosaria De Luca MD ,&nbsp;Michele Arcopinto MD, PhD ,&nbsp;Paola Gargiulo MD, PhD ,&nbsp;Valeria Valente MD ,&nbsp;Giulia Crisci MD ,&nbsp;Carmen Rainone MD ,&nbsp;Michele Modestino MD ,&nbsp;Federica Giardino MD ,&nbsp;Stefania Paolillo MD, PhD ,&nbsp;Francesco Cacciatore MD, PhD ,&nbsp;Lavinia Saldamarco MD ,&nbsp;Dario Bruzzese PhD ,&nbsp;Donatella Scarpa MD ,&nbsp;Pasquale Perrone Filardi MD, PhD ,&nbsp;Giovanni Esposito MD ,&nbsp;Luigi Saccà MD ,&nbsp;Eduardo Bossone MD, PhD ,&nbsp;Andrea Salzano MD, PhD ,&nbsp;Antonio Cittadini MD","doi":"10.1016/j.jchf.2024.11.017","DOIUrl":"10.1016/j.jchf.2024.11.017","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;div&gt;Growing evidence suggests that reduced activity of the growth hormone (GH)/insulin-like growth factor (IGF)-1 axis is common and associated with poor clinical status and outcome in heart failure (HF). In addition, preliminary results of growth hormone deficiency (GHD) correction in HF showed an improvement in quality of life, cardiac structure and function, and cardiovascular performance.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Objectives&lt;/h3&gt;&lt;div&gt;The aim of the present double-blind, randomized, placebo-controlled trial was to evaluate the cardiovascular effects of 1 year of GH replacement therapy in a cohort of patients with heart failure and reduced ejection fraction (HFrEF).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;Consecutive patients with HFrEF in NYHA functional class I/II/III and concomitant GHD were recruited. GHD patients were randomized to receive GH (0.012 mg/kg every second day ∼2.5 IU), or placebo, on top of background therapy. The primary endpoint was peak oxygen consumption (VO&lt;sub&gt;2&lt;/sub&gt;). Secondary endpoints included hospitalizations, end-systolic left ventricular volumes, N-terminal pro–B-type natriuretic peptide (NT-proBNP) levels, health-related quality of life score, and muscle strength (handgrip).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;A total of 318 consecutive patients were screened, with 86 (27%) fulfilling the criteria for GHD. Of these, 22 subjects refused to participate in the study. The final study groups consisted of 64 patients, 30 randomized in the active treatment group and 34 in the control group. After 1 year, 45 patients completed the study (21 in the control group and 24 in the active group). A statistically significant improvement of peak VO&lt;sub&gt;2&lt;/sub&gt; was reached in the active group (from 12.8 ± 3.4 mL/kg/min to 15.5 ± 3.15 mL/kg/min; &lt;em&gt;P &lt;&lt;/em&gt; 0.01; delta peak VO&lt;sub&gt;2&lt;/sub&gt; between groups: +3.1 vs −1.8; &lt;em&gt;P &lt;&lt;/em&gt; 0.01). Other cardiopulmonary exercise test parameters (ie, peak workload, VO&lt;sub&gt;2&lt;/sub&gt; at the aerobic threshold, O&lt;sub&gt;2&lt;/sub&gt; pulse and VE/VCO&lt;sub&gt;2&lt;/sub&gt; slope; &lt;em&gt;P &lt;&lt;/em&gt; 0.05) also improved, paralleled by an increase in 6-minute walking test distance (&lt;em&gt;P &lt;&lt;/em&gt; 0.05) and handgrip strength (&lt;em&gt;P &lt;&lt;/em&gt; 0.01). GH improved right ventricular function (ie, TAPSE and TAPSE/pulmonary artery systolic pressure ratio; &lt;em&gt;P &lt;&lt;/em&gt; 0.01), leading to an amelioration of clinical status (NYHA functional class; &lt;em&gt;P &lt;&lt;/em&gt; 0.05) and health-related quality of life (Minnesota Living With Heart Failure Questionnaire; &lt;em&gt;P &lt;&lt;/em&gt; 0.05). A significant decrease of NT-proBNP was also found (&lt;em&gt;P &lt;&lt;/em&gt; 0.05).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusions&lt;/h3&gt;&lt;div&gt;This randomized, double-blind, placebo-controlled trial demonstrates that GH replacement therapy in HFrEF patients with GHD improves exercise performance, and left ventricular and right ventricular structure and function, leading to an amelioration of clinical status and health-related quality of life. (Treatment of GHD A","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"13 4","pages":"Pages 602-614"},"PeriodicalIF":10.3,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143567154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of Histologic Findings With Long-Term Outcomes in Symptomatic Obstructive Hypertrophic Cardiomyopathy Patients Undergoing Surgical Myectomy","authors":"Shada Jadam MD,&nbsp;Andrew Gaballa MD,&nbsp;Alaa Alashi MD,&nbsp;Bo Xu MD,&nbsp;Maran Thamilarasan MD,&nbsp;E. Rene Rodriguez MD,&nbsp;Carmela D. Tan MD,&nbsp;Susan Ospina NP,&nbsp;Nicholas Smedira MD,&nbsp;Zoran B. Popovic MD, PhD,&nbsp;Milind Y. Desai MD, MBA","doi":"10.1016/j.jchf.2024.10.006","DOIUrl":"10.1016/j.jchf.2024.10.006","url":null,"abstract":"<div><h3>Background</h3><div>In hypertrophic cardiomyopathy, histologic findings like myocyte hypertrophy and disarray, interstitial fibrosis (IF), and small intramural coronary artery dysplasia (SICAD) result in left ventricular hypertrophy, diastolic dysfunction, arrhythmogenicity, and microvascular ischemia.</div></div><div><h3>Objectives</h3><div>The authors sought to evaluate the association between histology and outcomes in obstructive hypertrophic cardiomyopathy (oHCM) patients undergoing surgical myectomy (SM).</div></div><div><h3>Methods</h3><div>The study included 1,722 symptomatic oHCM patients (mean age: 56 ± 14 years; 948 [55%] men) who underwent SM at a tertiary center between 2005 and 2018. The SM specimen was analyzed for presence and severity of: 1) myocyte hypertrophy; 2) myocyte disarray; 3) IF; and 4) SICAD. Histologic findings were graded as 0-3 (none, mild, moderate, and severe) and a score from 0-12 was calculated. Primary endpoint was a composite of death, appropriate defibrillator discharge, or cardiac transplantation during follow-up.</div></div><div><h3>Results</h3><div>Moderate and severe histologic findings were distributed as follows: myocyte hypertrophy (1,341 [78%]); disarray (237 [14%]); IF (448 [26%]); and SICAD (258 [15%]). The mean total histologic score was 5.1 ± 1.4. At 5.1 ± 5.2 years, there were 352 (20%) primary events (317 [18%] deaths). On spline analysis, a total histology score of &gt;5 was associated with primary events. On Kaplan-Meier analysis, patients with a histology score &gt;5 had greater events vs those with a score ≤5 (147/598 [25%] vs 205/1124 [18%]; log-rank <em>P</em> = 0.002). On multivariable Cox analysis, total histology score &gt;5 (HR: 1.24 [95% CI: 1.03-1.54]; <em>P =</em> 0.03) was independently associated with higher primary events.</div></div><div><h3>Conclusions</h3><div>In symptomatic oHCM patients undergoing SM, a higher histologic score was independently associated with long-term outcomes.</div></div>","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"13 4","pages":"Pages 631-640"},"PeriodicalIF":10.3,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142638974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}